• 1
    Tubiana M, Malaise E. Growth rate and cell kinetics in human tumours. In SymingtonT, CarterR eds, Scientific Foundation of Oncology. Chicago: Year Book Medical Publishers, Inc. 1975: 126135
  • 2
    Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles’ heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 297282
  • 3
    Bostwick DG, Montironi R. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Pathol Res Pract 1995; 191: 82832
  • 4
    Denmeade SR, Lin ZS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 25165
  • 5
    Berges RR, Vukanovic J, Epstein JI et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 47380
  • 6
    Scher H, Isaacs J, Zelefsky M et al. Prostate cancer. In AbeloffM, ArmitageJ, LichterA, NiederhuberJ eds, Clinical Oncology, 2nd edn. New York: Churchill Livingstone Publishers, 2000
  • 7
    Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G0/G1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001; 61: 63726
  • 8
    Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 54557
  • 9
    Isaacs JT. Role of androgens in prostate cancer. Vitam Horm 1994; 49: 433502
  • 10
    Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2: 38996
  • 11
    Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 26373
  • 12
    American Cancer Society. Cancer Facts and Figures 2004[monograph on the Internet]. Atlanta: American Cancer Society, 2004. Accessed September 2005.
  • 13
    Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002; 9: 6173
  • 14
    Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004; 10: 267
  • 15
    Simons JW, Small E, Nelson W et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX®) demonstrate anti-tumor activity. Proc Am Soc Clin Oncol 2001; 20: A1073
  • 16
    Simons JW, Mikhak B, Chang JF et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 51608
  • 17
    Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 255963
  • 18
    DeWeese TL, Van Der Poel H, Li S et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 746472
  • 19
    Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 (Suppl. 1): 1523
  • 20
    Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 214958
  • 21
    Denmeade SR, Jakobsen CM, Janssen S et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95: 9901000
  • 22
    Christensen SB, Andersen A, Kromann H et al. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999; 17: 127380
  • 23
    DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 15185